Viridian Therapeutics, Inc.
NASDAQ:VRDNBiotechnology
-$0.15 today
- Market cap
- $3.42B
- Beta
- 0.90
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$3.53
Volume 1.49M
Average 2.86M
VRDN Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Viridian Therapeutics, Inc.NASDAQ: VRDN
Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026
Change in working capital dips below year-ago levels
Q2 FY2026 change in working capital of $3.37M fell 78.8% year over year, behind the +181.1% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +13.0% a year.
Context
- Change in working capital amounted to 32.5% of revenue in FY2025, down 3145.6 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -78.8% toward the trailing-twelve-month pace of +181.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 23.03M USD
- Year-over-year change
- +140.0%
- 4-year CAGR
- +91.2%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.03M | +140.0% |
| FY2024 | 2024-12-31 | 9.6M | +201.8% |
| FY2023 | 2023-12-31 | (9.43M) | -159.0% |
| FY2022 | 2022-12-31 | 15.96M | +825.9% |
| FY2021 | 2021-12-31 | 1.72M | — |
Change in Working Capital vs competitors
How VRDN compares with its peers on the latest reported figures
- VRDN's LTM Jun 2026 change in working capital of $3M is the smallest of the 4 companies compared; the peer median is $3.14M.
- Its year-over-year change of +181.1% is the 2nd highest of 4, against a peer median of +103.5%.
- Change in working capital amounts to 4.2% of revenue for VRDN, versus a peer median of 347.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $26.49M | +1949.9% | +123.6% | 347.8% | |
| LTM Mar 2026 | $6.94M | +103.5% | — | 2082.3% | |
| LTM Mar 2026 | $3.14M | -62.2% | +78.8% | 6.0% | |
| LTM Jun 2026 | $3M | +181.1% | +13.0% | 4.2% | |
| Peer median (excluding VRDN) | $3.14M | +103.5% | +101.2% | 347.8% | |
Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (79.41M) | (129.87M) | (237.73M) | (269.95M) | (342.6M) |
| Depreciation & Amortization | 120K | 255K | 522K | 540K | 460K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.47M | 19.77M | 67.17M | 42.15M | 44.3M |
| Change in Working Capital | 1.72M | 15.96M | (9.43M) | 9.6M | 23.03M |
| Accounts Receivables | (451K) | 349K | 0 | 102K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.66M | 11.52M | (12.04M) | (73K) | 6.56M |
| Other Working Capital | 520K | 4.09M | 2.62M | 9.57M | 16.47M |
| Other Non-Cash Items | 8.52M | 54K | (4.71M) | (14.66M) | (1.58M) |
| Operating Cash Flow | (54.58M) | (93.84M) | (184.17M) | (232.32M) | (276.39M) |
| Capital Expenditures | (338K) | (797K) | (898K) | (511K) | (495K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (188.43M) | (223.26M) | (407.88M) | (695.07M) | (579.28M) |
| Sales of Investments | 114.4M | 108.94M | 314.53M | 466.93M | 542.21M |
| Other Investing Activities | 79K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (74.29M) | (115.13M) | (94.25M) | (228.65M) | (37.56M) |
| Debt Repayment | 0 | 5M | 15M | 0 | 28.88M |
| Common Stock Issued | 114.24M | 291.87M | 125.07M | 453.66M | 348.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.93M) | (18.63M) | 9.41M | (20.92M) | 49.54M |
| Financing Cash Flow | 125.28M | 322.24M | 225.67M | 457.74M | 426.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (3.6M) | 113.28M | (52.75M) | (3.23M) | 112.79M |
| Free Cash Flow | (54.92M) | (94.64M) | (185.07M) | (232.83M) | (276.89M) |
Viridian Therapeutics, Inc.
NASDAQ:VRDN
Intrinsic Alpha fair value
Locked
Current Price
$30.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.